Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 14, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their personal holdings of the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transaction details.
- Share Transaction Price: GBP 11.07 per Ordinary share.
- Transaction Type: Re-investment of dividends paid to shareholders on April 10, 2008.
Material Changes
The filing details an increase in share interests for the following individuals following the dividend re-investment:
- Mr J S Heslop: 459 shares
- Mrs P A Heslop: 110 shares
- Mr D Learmouth: 106 shares
- Dr D Pulman: 207 shares
- Mrs C R Pulman: 69 shares
- Mr A P Witty: 34 shares
- Mrs C M Witty: 456 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to the requirements of Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director shareholdings.
Key Facts for Investor Verification
- Verify the dividend payment date of April 10, 2008, and the associated re-investment mechanism.
- Confirm the share price of GBP 11.07 on the transaction date.
- Review the total aggregate increase in holdings for the named directors and connected persons.
- Note that this filing contains no operational or financial performance data for the period.